The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
MDS 2023 | The rationale for combining magrolimab with ruxolitinib in myelofibrosis
Ciro Rinaldi, MD, PhD, Lincoln County Hospital, Lincoln, UK, highlights the rationale for combining the anti-CD47 antibody magrolimab with ruxolitinib in myelofibrosis (MF). Prof. Rinaldi discusses findings from his research group, including the overexpression of CD47 in MF stem cells and reduction of phagocytosis of neoplastic cells in patients with MF. Prof. Rinaldi further explains that combination of magrolimab led to an increase in the apoptosis of MF neoplastic cells. This interview took place at the 17th International Congress on Myelodysplastic Syndromes 2023 (MDS 2023) held in Marseille, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
